TrialBlood advances2025

Ixazomib decreases the risk of chronic graft-versus-host disease: identification of cGVHD biomarkers.

Teresa Caballero-Velázquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.